The aim of our study: to evaluate the efficacy of trazodone in the treatment of patients with depression showing marked insomnia.

45 patients, with diagnosis F32.0 -F32.2 (according to ICD -10) with marked insomnia, aged 29- 64 years, were enrolled. Patients received trazodone 15o mg/day, 6 weeks,without concomitant medication.The visits were organized at the beginning of treatment, after 2, and after 6 weeks of treatment for all the patients.The Montgomery Asberg Depression Rating Scale was used as a rating instruments.Gathered data were statistically processed.

There was a significant improvement for trazodone treated patients in the MADRS item 4 scores at weeks 2 and 6 versus baseline (p < 0,05).They also showed significant and clinically relevant improvement in MADRS total scores after trazodone treatment.

Trazodone shows a significant beneficial effect in reducing sleep disturbance in depressed patients.